OpenAlex
PricingAboutJobs
Log inGet started
Work

Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products

HTML

Year: 2008
Type: review
Source: Journal of Immunological Methods
DOI: 10.1016/j.jim.2008.01.001
Authors: Eugen Koren, Holly W. Smith, Elizabeth Shores, Gopi Shankar, Deborah Finco-Kent, Bonita Rup, Yu-Chen Barrett, Viswanath Devanarayan, Boris Gorovits, Shalini Gupta, Thomas Parish, Valerie Quarmby, Michael Moxness, Steven J. Swanson, Gary Taniguchi, Linda A. Zuckerman, Christopher C. Stebbins, Anthony Mire-Sluis
Institutions: Abbott Vascular (United States), Eli Lilly (United States), United States Food and Drug Administration, Center for Drug Evaluation and Research, Pfizer (United States), Wyeth, Bristol-Myers Squibb (United States), Merck & Co., Inc., Rahway, NJ, USA (United States), Amgen (United States), Procter & Gamble (United States), Genentech, PDL BioPharma (United States)
Language: English

Topic: Biosimilars and Bioanalytical Methods
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Keywords: anti-drug antibodies, immunogenicity, biopharmaceuticals, antibody detection, antibody characterization, adverse events, pharmacokinetics, pharmacodynamics, nonclinical studies, therapeutic proteins
SDG: Good health and well-being

Open Access status: closed
OpenAlex ID: W2138572955
FWCI: 2.174
Cites: 26
Cited by: 339
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms